Fig. 2

Progression-free survival for each of the comparison groups, a G-CSF + plerixafor versus G-CSF alone (comparison 1); b G-CSF + plerixafor versus G-CSF + chemotherapy (comparison 2); and c G-CSF + plerixafor + chemotherapy versus G-CSF + chemotherapy (comparison 3)